TY  - JOUR
AU  - Lorente, David
AU  - Olmos, David
AU  - Mateo, Joaquin
AU  - Bianchini, Diletta
AU  - Seed, George
AU  - Fleisher, Martin
AU  - Danila, Daniel C.
AU  - Flohr, Penny
AU  - Crespo, Mateus
AU  - Figueiredo, Ines
AU  - Miranda, Susana
AU  - Baeten, Kurt
AU  - Molina, Arturo
AU  - Kheoh, Thian
AU  - McCormack, Robert
AU  - Terstappen, Leon W. M. M.
AU  - Scher, Howard I.
AU  - de-Bono, Johann S.
PY  - 2017
DO  - 10.1016/j.eururo.2016.05.023
SN  - 0302-2838
UR  - http://hdl.handle.net/10668/18775
T2  - European urology
AB  - Background: Treatment response biomarkers are urgently needed for castration-resistant prostate cancer (CRPC). Baseline and post-treatment circulating tumor cell (CTC) counts of >= 5 cells/7.5 ml are associated with poor CRPC outcome.Objective: To...
LA  - en
PB  - Elsevier science bv
KW  - Castration-resistant prostate cancer
KW  - Treatment outcome
KW  - Response
KW  - Circulating tumor cells
KW  - Abiraterone
KW  - Chemotherapy
KW  - Abiraterone acetate
KW  - Increased survival
KW  - End-points
KW  - Chemotherapy
KW  - Enzalutamide
KW  - Antigen
KW  - Trial
KW  - Surrogacy
KW  - Docetaxel
KW  - Biomarker
KW  - Androstenes
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cell Count
KW  - Clinical Trials as Topic
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Logistic Models
KW  - Male
KW  - Multivariate Analysis
KW  - Neoplasm Metastasis
KW  - Neoplastic Cells, Circulating
KW  - Prednisone
KW  - Proportional Hazards Models
KW  - Prostatic Neoplasms, Castration-Resistant
TI  - Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
TY  - research article
VL  - 70
ER  -